Breast Cancer Research and Treatment

, Volume 140, Issue 3, pp 453–462 | Cite as

Everolimus: side effect profile and management of toxicities in breast cancer

  • Elisavet Paplomata
  • Amelia Zelnak
  • Ruth O’Regan


Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR), which has been approved in combination with exemestane for hormone receptor-positive (HR) breast cancer after failure of treatment with non-steroidal aromatase inhibitors. Everolimus is generally very well tolerated with most common side effects including stomatitis, rash, fatigue, hyperglycemia, hyperlipidemia, and myelosuppression. Most of these side effects are mild and resolve with dose interruptions or dose reductions. Symptomatic non-infectious pneumonitis is a relatively uncommon class effect of mTOR inhibitors, which can be life threatening. Given the efficacy of everolimus in HR-positive metastatic breast cancer, it is crucial for physicians to recognize toxicities related to everolimus and start timely interventions. This review will focus on the adverse events reported with everolimus in breast cancer trials and will provide practical guidelines for the management of these adverse events.


Everolimus Side effects Non-infectious pneumonitis mTOR inhibitors Breast cancer 


Conflict of interest

Dr. Paplomata and Dr. Zelnak have nothing to disclose. Dr. O’Regan acts as consultant/advisory role for Novartis.


  1. 1.
    Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi: 10.3322/caac.21166 PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics. CA Cancer J Clin 62(4):220–241. doi: 10.3322/caac.21149 PubMedCrossRefGoogle Scholar
  3. 3.
    Huang S, Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3(4):371–377PubMedCrossRefGoogle Scholar
  4. 4.
    Baselga J (2011) Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16(Suppl 1):12–19. doi: 10.1634/theoncologist.2011-S1-12 PubMedCrossRefGoogle Scholar
  5. 5.
    Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New Engl J Med 366(6):520–529. doi: 10.1056/NEJMoa1109653 PubMedCrossRefGoogle Scholar
  6. 6.
    Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaeth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718–2724. doi: 10.1200/JCO.2011.39.0708 PubMedCrossRefGoogle Scholar
  7. 7.
    Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nunez R, Hortobagyi GN, Yu D, Esteva FJ (2011) Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29(23):3126–3132. doi: 10.1200/JCO.2010.32.2321 PubMedCrossRefGoogle Scholar
  8. 8.
    Andre F, Campone M, O’Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28(34):5110–5115. doi: 10.1200/JCO.2009.27.8549 PubMedCrossRefGoogle Scholar
  9. 9.
    US Food and Drug Administration, Everolimus (2012). Accessed in May 7 2013
  10. 10.
    Hoffman R (2013) Hematology : basic principles and practice, 6th edn. Elsevier/Saunders, PhiladelphiaGoogle Scholar
  11. 11.
    O’Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26(10):1588–1595. doi: 10.1200/JCO.2007.14.0988 PubMedCrossRefGoogle Scholar
  12. 12.
    Kirchner GI, Meier-Wiedenbach I, Manns MP (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43(2):83–95PubMedCrossRefGoogle Scholar
  13. 13.
    Barnett CM (2012) Everolimus: targeted therapy on the horizon for the treatment of breast cancer. Pharmacotherapy 32(4):383–396. doi: 10.1002/j.1875-9114.2012.01084.x PubMedCrossRefGoogle Scholar
  14. 14.
    Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, Lasseter K, Rordorf C (2001) Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 70(5):425–430PubMedGoogle Scholar
  15. 15.
    Awada A, Cardoso F, Fontaine C, Dirix L, De Greve J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M (2008) The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 44(1):84–91. doi: 10.1016/j.ejca.2007.10.003 PubMedCrossRefGoogle Scholar
  16. 16.
    Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T, Gianni L (2011) Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 125(2):447–455. doi: 10.1007/s10549-010-1260-x PubMedCrossRefGoogle Scholar
  17. 17.
    Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT (2012) A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378–2384. doi: 10.1002/cncr.26571 PubMedCrossRefGoogle Scholar
  18. 18.
    Schwarzlose-Schwarck S, Scholz CW, Regierer AC, Martus P, Neumann C, Habbel P, Liu H, Zang C, Schefe JH, Schulz CO, Possinger K, Eucker J (2012) The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer–a phase I trial. Anticancer Res 32(8):3435–3441PubMedGoogle Scholar
  19. 19.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630–2637. doi: 10.1200/JCO.2008.18.8391 PubMedCrossRefGoogle Scholar
  20. 20.
    Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27(27):4536–4541. doi: 10.1200/JCO.2008.21.3033 PubMedCrossRefGoogle Scholar
  21. 21.
    Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H (2012) Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 17(1):135–144. doi: 10.1634/theoncologist.2011-0111 PubMedCrossRefGoogle Scholar
  22. 22.
    Sonis S, Treister N, Chawla S, Demetri G, Haluska F (2010) Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116(1):210–215. doi: 10.1002/cncr.24696 PubMedGoogle Scholar
  23. 23.
    de Oliveira MA, Martins EMF, Wang Q, Sonis S, Demetri G, George S, Butrynski J, Treister NS (2011) Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 47(10):998–1003. doi: 10.1016/j.oraloncology.2011.08.009 PubMedCrossRefGoogle Scholar
  24. 24.
    Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S, Treister N (2013) A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 49(4):293–298. doi: 10.1016/j.oraloncology.2012.11.008 PubMedCrossRefGoogle Scholar
  25. 25.
    Nicolatou-Galitis O, Nikolaidi A, Athanassiadis I, Papadopoulou E, Sonis S (2013) Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Oral Surg Oral Med Oral Pathol Oral Radiol. doi: 10.1016/j.oooo.2013.02.022 PubMedGoogle Scholar
  26. 26.
    Peterson ME (2013) Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer 21(8):2341–2349. doi: 10.1007/s00520-013-1826-3 PubMedCrossRefGoogle Scholar
  27. 27.
    Ferte C, Paci A, Zizi M, Gonzales DB, Goubar A, Gomez-Roca C, Massard C, Sahmoud T, Andre F, Soria JC (2011) Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer 47(15):2249–2255. doi: 10.1016/j.ejca.2011.03.017 PubMedCrossRefGoogle Scholar
  28. 28.
    Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22(12):2336–2347. doi: 10.1200/JCO.2004.08.116 PubMedCrossRefGoogle Scholar
  29. 29.
    AFINITOR [prescribing information] (2012) Novartis Pharmaceuticals Corporation, East Hanover, NJGoogle Scholar
  30. 30.
    Ramirez-Fort MK, Case EC, Rosen AC, Cerci FB, Wu S, Lacouture ME (2012) Rash to the mTOR Inhibitor everolimus: systematic review and meta-analysis. Am J Clin Oncol. doi: 10.1097/COC.0b013e318277d62f
  31. 31.
    Soefje SA, Karnad A, Brenner AJ (2011) Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol 6(2):125–129. doi: 10.1007/s11523-011-0174-9 PubMedCrossRefGoogle Scholar
  32. 32.
    Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E (2010) mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 24(2):149–156. doi: 10.1111/j.1399-0012.2010.01232.x PubMedCrossRefGoogle Scholar
  33. 33.
    Huffman TA, Mothe-Satney I, Lawrence JC Jr (2002) Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci USA 99(2):1047–1052. doi: 10.1073/pnas.022634399 PubMedCrossRefGoogle Scholar
  34. 34.
    Alasker A, Meskawi M, Sun M, Ismail S, Hanna N, Hansen J, Tian Z, Bianchi M, Perrotte P, Karakiewicz PI (2013) A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer Treat Rev 39(4):388–401. doi: 10.1016/j.ctrv.2012.12.006 PubMedCrossRefGoogle Scholar
  35. 35.
    Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, R-S Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456. doi: 10.1016/S0140-6736(08)61039-9 PubMedCrossRefGoogle Scholar
  36. 36.
    Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A, R-S Group (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265. doi: 10.1002/cncr.25219 PubMedCrossRefGoogle Scholar
  37. 37.
    Appleby L, Morrissey S, Bellmunt J, Rosenberg J (2011) Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. Hematol Oncol Clin North Am 25(4):893–915. doi: 10.1016/j.hoc.2011.05.004 PubMedCrossRefGoogle Scholar
  38. 38.
    Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes A, European Association for Study of D (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1):193–203. doi: 10.2337/dc08-9025 PubMedCrossRefGoogle Scholar
  39. 39.
    Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13(10):1084–1096. doi: 10.1634/theoncologist.2008-0120 PubMedCrossRefGoogle Scholar
  40. 40.
    Seruga B, Gan HK, Knox JJ (2009) Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer. Curr Oncol 16(Suppl 1):S52–S59PubMedGoogle Scholar
  41. 41.
    Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M (2006) Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42(12):1875–1880. doi: 10.1016/j.ejca.2006.03.015 PubMedCrossRefGoogle Scholar
  42. 42.
    Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, Cincotta M, Shapiro M, Duran I, Berkenblit A (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 29(13):1750–1756. doi: 10.1200/JCO.2010.29.2235 PubMedCrossRefGoogle Scholar
  43. 43.
    White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182(3):396–403. doi: 10.1164/rccm.200911-1720OC PubMedCrossRefGoogle Scholar
  44. 44.
    Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E (2012) Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 51(7):873–879. doi: 10.3109/0284186X.2012.705019 PubMedCrossRefGoogle Scholar
  45. 45.
    Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, Singer J, Shah T, Wilkinson AH (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77(8):1215–1220PubMedCrossRefGoogle Scholar
  46. 46.
    Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, Pedrosa I, Choueiri TK (2012) Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 48(10):1519–1524. doi: 10.1016/j.ejca.2012.03.012 PubMedCrossRefGoogle Scholar
  47. 47.
    Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ (2011) Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 47(9):1287–1298. doi: 10.1016/j.ejca.2011.02.014 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Elisavet Paplomata
    • 1
  • Amelia Zelnak
    • 1
  • Ruth O’Regan
    • 1
  1. 1.Department of Hematology and Medical OncologyWinship Cancer Institute of Emory UniversityAtlantaUSA

Personalised recommendations